Circulating vaccine-derived poliovirus type 2 – Democratic Republic of the CongoIn the Democratic Republic of the Congo (DRC), two separate circulating vaccine-derived poliovirus type 2s (cVDPV2s) have been confirmed. WHO will continue to evaluate the epidemiological situation and outbreak response measures being implemented. As per the advice of the Emergency Committee convened under the International Health Regulations (2005), efforts to limit the international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC). WHO risk assessmentWHO assesses the risk of further national spread of these strains to be high, and the risk of international spread to be medium. A robust outbreak response as initiated is needed to rapidly stop circulation and ensure sufficient vaccination coverage in the affected areas to prevent similar outbreaks in the future.
WHO briefing notes on vaccine-derived poliovirus type 2 in Syria, Update as of 16 June 2017 - Syrian Arab Republic
Most recently, two campaigns have been conducted in March and April 2017 using bivalent oral polio vaccine (bOPV). The detection of cVDPV2 underscores the importance of maintaining high levels of routine vaccination coverage at all levels to minimize the risk and consequences of any poliovirus circulation. Such events also underscore the risk in areas or regions with continued substantial insecurity that hampers maintaining high population immunity through routine vaccination. Oral polio vaccine (OPV) contains an attenuated (weakened) vaccine-virus, activating an immune response in the body. No new cases of vaccine-derived poliovirus type 2 have been confirmed since our last communication on 13 June, though of course disease surveillance is ongoing in Deir Al Zour.collected by :Lucy William
No comments:
Post a Comment